Intermittent, reversible intraabdominal vagal blockade (VBLOC® Therapy) demonstrated clinically important weight loss in feasibility trials. EMPOWER, a randomized, double-blind, prospective, controlled trial was conducted in USA and Australia.
Five hundred three subjects were enrolled at 15 centers. After informed consent, 294 subjects… (More)
Figures and Tables
Sorry, we couldn't extract any figures or tables for this paper.